medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2005, Number 4

<< Back Next >>

Rev Biomed 2005; 16 (4)

Activation of dopaminergic receptors by L-DOPA. From therapeutics to dyskinesia.

Florán-Garduño B, Rangel-Barajas C

Language: Spanish
References: 65
Page: 273-280
PDF size: 160.17 Kb.


ABSTRACT

L-DOPA is still the pharmacological treatment of choice for Parkinson disease. In the present work, we show and discuss the basis of the main mechanism of action of L-DOPA that explains its therapeutic effect: dopamine replacement. At the same time we question the generation of dyskinesia by a replacement mechanism and shown the experimental findings that help to understand it. Additional mechanisms including direct activation of dopamine receptors, and the existence of a DOPAergic system might contribute to the explanation. We believe that better understanding of the action of L-DOPA in Parkinson's disease will help in the development of new pharmacological treatments.


REFERENCES

  1. 1.- Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 2002; 23:65-70.

  3. 2.- Barbeu A, Murphy GF, Sourkes TL. Excretion of dopamine in diseases of basal ganglia. Science 1961; 133:1706-7.

  5. 3.- Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001; 2:577-88.

  7. 4.- Dluzen D, Reddy A, McDermott J. The aromatic amino acid decarboxylase inhibitor, NSD-1015, increases release of dopamine: response characteristics. Neuropharmacology 1992; 31:1223-9.

  9. 5.- Hornykiewicz O. The mechanisms of action of L-dopa in Parkinson's disease. Life Sci 1974; 15:1249-59.

  11. 6.- Lopez A, Munoz A, Guerra MJ, Labandeira-Garcia JL. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 2001; 103:639-51.

  13. 7.- Nakazato T, Akiyama A. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. Brain Res 2002; 930:134-42.

  15. 8.- Whone AL, Watts RL, Stoess AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003; 54:93-101.

  17. 9.- Pearce RK, Heikkila M, Linden IB, Jenner P. L-DOPA induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berl) 2001; 156:402-9.

  19. 10.- Ikemoto K. Significance of human striatal D-neurons: implications in neuropsychiatric functions. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:429-34.

  21. 11.- Luthman J, Bolioli B, Tsutsumi T. Verhofstad A, Jonsson G. Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Res Bull 1987; 19:269-74.

  23. 12.- Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 10:631-4.

  25. 13.- Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, et al. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 2003; 343:17-20.

  27. 14.- Misu Y, Goshima Y, Ueda H, Okamura H. Neurobiology of L-DOPAergic systems. Prog Neurobiol 1996; 49:415-54.

  29. 15.- Boraud T, Bezard E, Guehl D, Bioulac B, Gross C. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res 1998; 787:157-60.

  31. 16.- Aceves J, Floran B, Martinez-Fong D, Sierra A, Hernandez S, Mariscal S. L-DOPA stimulates the release of. Neurosci Lett 1991; 121:223-6.

  33. 17.- Cossette M, Levesque M, Parent A. Extrastriatal dopaminergic innervation of human basal ganglia. Neurosci Res 1999; 34:51-4.

  35. 18.- Penney JB, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci 1983; 6:73-94.

  37. 19.- Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003; 304:792-800.

  39. 20.- Chartoff EH, Marck BT, Matsumoto AM, Dorsa DM, Palmiter RD. Induction of stereotypy in dopamine-deficient mice requires striatal D1 receptor activation. Proc Natl Acad Sci U S A 2001; 98:10451-6.

  41. 21.- Gerfen CR, Miyachi S, Paletzki R, Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase J Neurosci 2002; 22:5042-54.

  43. 22.- Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma F, et al. D. R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250:1429-32.

  45. 23.- Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005; 57:17-26.

  47. 24.- Nakazato T, Akiyama A. Effect of exogenous L-dopa on behavior in the rat: an in vivo voltammetric study. Brain Res 1989; 490:332-8.

  49. 25.- Nakamura S, Yue JL, Goshima Y, Miyamae T, Ueda H, Misu Y. Non-effective dose of exogenously applied L-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Neurosci Lett 1994; 170:22-6.

  51. 26.- Yue JL, Nakamura S, Ueda H, Misu Y. Endogenously released L-dopa itself tonically functions to potentiate postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Neurosci Lett 1994; 170:107-10.

  53. 27.- Fisher A, Biggs CS, Eradiri O, Starr, M. S. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent. Neuroscience 2000; 95:97-111.

  55. 28.- Goshima Y, Nakamura S, Misu Y. L-dihydroxyphenylalanine methyl ester is a potent competitive antagonist of the L-dihydroxyphenylalanine-induced facilitation of the evoked release of endogenous norepinephrine from rat hypothalamic slices. J Pharmacol Exp Ther 1991; 258:466-71.

  57. 29.- Misu Y, Goshima Y, Miyamae T. Is DOPA a neurotransmitter? Trends Pharmacol Sci 2002; 23:262-8.

  59. 30.- Yue JL, Okamura H, Goshima Y, Nakamura S, Geffard M, Misu Y. Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats. Neuroscience 1994; 62:145-61.

  61. 31.- Treseder SA, Rose S, Jenner P. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats. Eur J Neurosci 2001; 13:162-70.

  63. 32.- Newman-Tancredi A, Audinot V, Chaput C, Verriele L, Millan MJ. [35S]Guanosine-5'-O-(3-thio) triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. J Pharmacol Exp Ther 1997; 282:181-91.

  65. 33.- O'Sullivan GJ, Roth BL, Kinsella A, Waddington JL. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography. Eur J Pharmacol 2004; 486:273-80.




2020     |     www.medigraphic.com